SEC Form 4 · accession 0001209191-15-035356

ZEVRA THERAPEUTICS, INC. · ZVRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President & CEO · Director · 10% Owner

Period of report

Apr 21, 2015

Accepted (ET)

Apr 21, 2015 · 6:45 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001434647

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Apr 21, 2015	C	5,983	—	A	277,094	I	By Spouse
Common Stock^F1,F2,F3	Apr 21, 2015	C	96,288	—	A	96,288	D
Common Stock	holding	—	—		—	1,538,373	D
Common Stock	holding	—	—		—	230,812	I	By Travis C Mickle & Christal M.M. Mickle TRS UA 4-30-09
Common Stock	holding	—	—		—	230,812	I	By Travis C Mickle & Christal M.M. Mickle TRS UA 4-30-09

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F3,F2	—	Apr 21, 2015	C	527,093	D	—	—	Common Stock	70,279	0	D
Series B Convertible Preferred Stock^F3,F2	—	Apr 21, 2015	C	6,203	D	—	—	Common Stock	827	0	D
Series C Convertible Preferred Stock^F3,F2	—	Apr 21, 2015	C	51,332	D	—	—	Common Stock	6,844	0	D
Series C Convertible Preferred Stock^F2	—	Apr 21, 2015	C	44,873	D	—	—	Common Stock	5,983	0	I
Series D Convertible Preferred Stock^F3,F2	—	Apr 21, 2015	C	137,541	D	—	—	Common Stock	18,338	0	D
Warrant to Purchase Series D Preferred Stock (right to buy)^F3,F2	—	Apr 21, 2015	C	32,371	D	—	—	Common Stock	4,316	0	D
Warrant to Purchase Common Stock (right to buy)^F3,F4,F5	$5.85	Apr 21, 2015	C	4,316	D	—	—	Common Stock	4,316	4,316	D

F1The total represents shares received upon conversion of Series A, Series B, Series C and Series D convertible preferred stock.
F2Effective upon the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B, Series C and Series D convertible preferred stock automatically converted into 0.13333 shares of common stock. The convertible preferred stock had no expiration date.
F3Held jointly with spouse.
F4Represents a warrant to purchase shares of common stock of the Issuer following the conversion of the Series D convertible preferred stock on a 1-for-0.1333 share basis. The number of shares and price per share reported herein reflects such conversion. The warrant is immediately exercisable at any time at the option of the holder.
F5The warrant expires as of 5:00 p.m. C.S.T. on the earliest of (i) June 2, 2019 and (ii) the effective date of the closing of a Company Sale Transaction (as such term is defined in the warrant).